Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review.

Authors:
McCaughan GJ; Gandolfi S; Moore JJ; Richardson PG.

Journal:
Br J Haematol

Publication Year: 2022

DOI:
10.1111/bjh.18295

PMCID:
PMC9796722

PMID:
35796524

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Br J Haematol

Abbreviation: Br J Haematol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Hematology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Accumulation of foamy macrophages in the bone marrow following chronic intravenous drug use.
Kyla Y; Penelope K; Kerry BM and 1 more (2022) - Transparency Score: 1/6
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with elt…
Al-Samkari H; Jiang D; Gernsheimer T and 5 more (2022) - Transparency Score: 3/6
Antithrombin-III mitigates thrombin-mediated endothelial cell contraction and sickle red blood cell…
Wulftange WJ; Kucukal E; Man Y and 10 more (2022) - Transparency Score: 4/6
A survey on thromboprophylaxis and coagulation assessment in children and young adults with acute l…
Andersson NG; Rathe M; Mølle I and 12 more (2022) - Transparency Score: 3/6
BCR::ABL1 transcripts and clinical outcome - interrogating the technique.
Branford S. (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICT OF INTEREST Georgia J. McCaughan reports advisory board participation and honoraria from Janssen. Paul G. Richardson reports institutional grant support from Bristol Myers Squibb/Celgene, Karyopharm, Oncopeptides AB, and Takeda; consulting fees for advisory committee service from Bristol Myers Squibb/Celgene, Karyopharm, Oncopeptides AB, GlaxoSmithKline, Janssen, Sanofi, and Takeda. Sara Gandolfi and John J. Moore have no conflicts of interest."

Evidence found in paper:

"FUNDING INFORMATION We acknowledge the funding support of the James Symond Family Multiple Myeloma Research Fund and the RJ Corman Multiple Myeloma Research Fund."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025